Andrew Murphy - Globus Medical Group President Commercial Operations
| GMED Stock | USD 51.25 0.90 1.79% |
President
Mr. Andrew Brett Murphy is Executive Vice President International Sales of the Company. Mr. Murphy served as our Executive Vice President, U.S. Sales from February 2011 to September 2015, as our Vice President, U.S. SalesWest, from November 2006 to February 2011, and as the Area Director for our South region from June 2005 to November 2006. Prior to joining Globus, Mr. Murphy served in various sales and management roles at Synthes from July 1995 to May 2005. Between November 1992 and June 1995, Mr. Murphy was a sales representative for Smith Nephew Richards. Mr. Murphy also served as an officer in the United States Marine Corporationration between 1987 and 1992 since 2018.
| Age | 52 |
| Tenure | 6 years |
| Address | 2560 General Armistead Avenue, Audubon, PA, United States, 19403 |
| Phone | 610 930 1800 |
| Web | https://www.globusmedical.com |
Andrew Murphy Latest Insider Activity
Tracking and analyzing the buying and selling activities of Andrew Murphy against Globus Medical stock is an integral part of due diligence when investing in Globus Medical. Andrew Murphy insider activity provides valuable insight into whether Globus Medical is net buyers or sellers over its current business cycle. Note, Globus Medical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Globus Medical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Andrew Murphy over three weeks ago Disposition of tradable shares by Andrew Murphy of Regeneron Pharmaceuticals at 962.87 subject to Rule 16b-3 | ||
Andrew Murphy over three months ago Acquisition by Andrew Murphy of 911 shares of Duos Technologies subject to Rule 16b-3 | ||
Andrew Murphy over six months ago Acquisition by Andrew Murphy of 1538 shares of Duos Technologies subject to Rule 16b-3 | ||
Andrew Murphy over six months ago Acquisition by Andrew Murphy of 325 shares of Duos Technologies subject to Rule 16b-3 |
Globus Medical Management Efficiency
The company has return on total asset (ROA) of 0.0477 % which means that it generated a profit of $0.0477 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0421 %, meaning that it created $0.0421 on every $100 dollars invested by stockholders. Globus Medical's management efficiency ratios could be used to measure how well Globus Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of April 23, 2024, Return On Tangible Assets is expected to decline to 0.04. In addition to that, Return On Capital Employed is expected to decline to 0.03. At present, Globus Medical's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 82.5 M, whereas Return On Tangible Assets are forecasted to decline to 0.04.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Kevin Karas | National Research Corp | 60 | |
| William Otten | HealthEquity | 52 | |
| Jeffery Doster | HealthStream | 51 | |
| Michael Collier | HealthStream | 48 | |
| Ashley Dreier | HealthEquity | 44 | |
| Edward Bloomberg | HealthEquity | 41 | |
| Trisha Coady | HealthStream | 48 | |
| Mollie Condra | HealthStream | N/A | |
| Angelique Hill | HealthEquity | 55 | |
| Edward Pearson | HealthStream | 61 | |
| Gary Robinson | HealthEquity | 55 | |
| Thomas Schultz | HealthStream | 49 | |
| Frode Jensen | HealthEquity | 64 | |
| Michael Sousa | HealthStream | 55 | |
| Jeffrey Cunningham | HealthStream | 57 | |
| Steven Jackson | National Research Corp | 42 | |
| Delano Ladd | HealthEquity | 43 | |
| Jonathan Soldan | HealthEquity | 32 | |
| Jonathan Maack | Definitive Healthcare Corp | 45 | |
| Scott McQuigg | HealthStream | 50 | |
| Larry Trittschuh | HealthEquity | 52 | |
Management Performance
| Return On Equity | 0.0421 | ||||
| Return On Asset | 0.0477 |
Globus Medical Leadership Team
Elected by the shareholders, the Globus Medical's board of directors comprises two types of representatives: Globus Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Globus. The board's role is to monitor Globus Medical's management team and ensure that shareholders' interests are well served. Globus Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Globus Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steve Zarrilli, Independent Director | ||
| David Paul, Co-Founder, Chairman, CEO, Chairman of Compensation Committee and Chairman of Nominating and Corporate Governance Committee | ||
| Eric Schwartz, Senior Vice President General Counsel | ||
| Mike Reeder, Ex Officer | ||
| Ann Rhoads, Independent Director | ||
| Robert Douglas, Independent Director | ||
| Andrew Murphy, Group President Commercial Operations | ||
| Steven Payne, VP Controller | ||
| Anthony Williams, Senior Vice President General Counsel | ||
| Kelly Esq, General VP | ||
| Kelly Huller, Senior Vice President General Counsel, Corporate Secretary | ||
| Stephen Zarrilli, Independent Director | ||
| Robert Liptak, Independent Director | ||
| James Tobin, Independent Director | ||
| Kurt Wheeler, Independent Director | ||
| Brian Kearns, Senior Relations | ||
| Brett Murphy, Group President of Commercial Operations | ||
| Richard Holifield, Ex Officer | ||
| Daniel Lemaitre, Independent Director | ||
| John Dowling, Ex Officer | ||
| Keith Pfeil, Chief Financial Officer, Senior Vice President | ||
| David Demski, Group President of Emerging Technologies, Director and Member of Nominating and Corporate Governance Committee | ||
| Daniel Scavilla, Executive Vice President, Chief Commercial Officer and President - Trauma | ||
| David Davidar, Co-Founder, Sr. VP of Operations and Director |
Globus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Globus Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0421 | ||||
| Return On Asset | 0.0477 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 6.82 B | ||||
| Shares Outstanding | 112.94 M | ||||
| Shares Owned By Insiders | 0.79 % | ||||
| Shares Owned By Institutions | 97.29 % | ||||
| Number Of Shares Shorted | 7.76 M | ||||
| Price To Earning | 73.16 X |
Globus Medical Investors Sentiment
The influence of Globus Medical's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Globus. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Globus Medical's public news can be used to forecast risks associated with an investment in Globus. The trend in average sentiment can be used to explain how an investor holding Globus can time the market purely based on public headlines and social activities around Globus Medical. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Globus Medical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Globus Medical's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Globus Medical's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Globus Medical.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Globus Medical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Globus Medical's short interest history, or implied volatility extrapolated from Globus Medical options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Globus Medical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For information on how to trade Globus Stock refer to our How to Trade Globus Stock guide.Note that the Globus Medical information on this page should be used as a complementary analysis to other Globus Medical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Globus Stock analysis
When running Globus Medical's price analysis, check to measure Globus Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Globus Medical is operating at the current time. Most of Globus Medical's value examination focuses on studying past and present price action to predict the probability of Globus Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Globus Medical's price. Additionally, you may evaluate how the addition of Globus Medical to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Globus Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Globus Medical. If investors know Globus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Globus Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.79) | Earnings Share 1.07 | Revenue Per Share 13.87 | Quarterly Revenue Growth 1.246 | Return On Assets 0.0477 |
The market value of Globus Medical is measured differently than its book value, which is the value of Globus that is recorded on the company's balance sheet. Investors also form their own opinion of Globus Medical's value that differs from its market value or its book value, called intrinsic value, which is Globus Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Globus Medical's market value can be influenced by many factors that don't directly affect Globus Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Globus Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Globus Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Globus Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.